184 related articles for article (PubMed ID: 32600864)
1. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions.
Cheng CN; Wu CC; Kuo CH; Wang CC; Wang JT; Lin YT; Jhang RS; Lin SW
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):466-475. PubMed ID: 32600864
[TBL] [Abstract][Full Text] [Related]
2. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
[TBL] [Abstract][Full Text] [Related]
3. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
Pea F; Cojutti PG; Baraldo M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737
[TBL] [Abstract][Full Text] [Related]
4. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
5. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
[TBL] [Abstract][Full Text] [Related]
6. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study.
Cojutti PG; Merelli M; Bassetti M; Pea F
J Antimicrob Chemother; 2019 Dec; 74(12):3588-3595. PubMed ID: 31504570
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
Crass RL; Cojutti PG; Pai MP; Pea F
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
[TBL] [Abstract][Full Text] [Related]
8. Dose optimisation of linezolid in critically ill patients based on a population pharmacokinetic model: A two-centre prospective interventional study.
Shi L; Zhang Y; Duan L; Huang L; Li J; Lu J; Zhuang Z; Yuan Y; Feng Z; Sun J; Liu X; Zhou Q; Xue H; Xu J; Tang L
Int J Antimicrob Agents; 2023 Aug; 62(2):106881. PubMed ID: 37301313
[TBL] [Abstract][Full Text] [Related]
9. Risk factors associated with high linezolid trough plasma concentrations.
Morata L; De la Calle C; Gómez-Cerquera JM; Manzanedo L; Casals G; Brunet M; Cobos-Trigueros N; Martínez JA; Mensa J; Soriano A
Expert Opin Pharmacother; 2016 Jun; 17(9):1183-7. PubMed ID: 27156708
[TBL] [Abstract][Full Text] [Related]
10. Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more.
Xu Y; Yang X; Liang P; Qu C
BMC Infect Dis; 2023 Nov; 23(1):840. PubMed ID: 38030977
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics.
Rao GG; Konicki R; Cattaneo D; Alffenaar JW; Marriott DJE; Neely M;
Ther Drug Monit; 2020 Feb; 42(1):83-92. PubMed ID: 31652190
[TBL] [Abstract][Full Text] [Related]
12. Initial trough concentration may be beneficial in preventing linezolid-induced thrombocytopenia.
Komatsu T; Nakamura M; Uchiyama K; Inoue G; Sakanoue K; Kawamura A; Hiratsuka K; Takayama Y; Takaso M; Atsuda K
J Chemother; 2022 Oct; 34(6):375-380. PubMed ID: 35209803
[TBL] [Abstract][Full Text] [Related]
13. Linezolid Induced Adverse Drug Reactions - An Update.
Kishor K; Dhasmana N; Kamble SS; Sahu RK
Curr Drug Metab; 2015; 16(7):553-9. PubMed ID: 26424176
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients.
Wicha SG; Mair A; Chiriac U; Frey OR; Fuchs T; Gaasch M; Hagel S; Richter DC; Roberts JA; Röhr AC; Weigand MA; Brinkmann A
Int J Antimicrob Agents; 2022 May; 59(5):106572. PubMed ID: 35307562
[TBL] [Abstract][Full Text] [Related]
15. A standard dose of linezolid puts patients with hepatic impairment at risk of overexposure.
Liao R; Dong Y; Chen L; Wang T; Li H; Dong H
Eur J Clin Pharmacol; 2023 Jan; 79(1):149-157. PubMed ID: 36434292
[TBL] [Abstract][Full Text] [Related]
16. Early linezolid-associated lactic acidosis in a patient with Child's class C liver cirrhosis and end stage renal disease.
Cheng CN; Lin SW; Wu CC
J Infect Chemother; 2018 Oct; 24(10):841-844. PubMed ID: 29503228
[TBL] [Abstract][Full Text] [Related]
17. Establishment and validation of a risk prediction model incorporating concentrations of linezolid and its metabolite PNU142300 for linezolid-induced thrombocytopenia.
Xu J; Lu J; Yuan Y; Duan L; Shi L; Chen F; Cao Y; Xu G; Feng Z; Li L; Xue H; Sun J; Zhou Q; Zhuang Z; Tang L
J Antimicrob Chemother; 2023 Aug; 78(8):1974-1981. PubMed ID: 37341139
[TBL] [Abstract][Full Text] [Related]
18. LInezolid Monitoring to MInimise Toxicity (LIMMIT1): A multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring.
Lau C; Marriott D; Bui J; Figtree M; Gould M; Chubaty A; Su Y; Adhikari S; Konecny P; Kozierowski K; Holland T; Milliken E; Akram A; Mcnamara A; Sun Y; Van Hal S; Patanwala AE; Shahabi-Sirjani A; Gray T; Yeo CY; Netluch A; Halena S; Appay M; Alameddine R; Yin F; Nguyen Q; So MY; Sandaradura I; Kim HY; Galimam S; Cerruto N; Lai T; Gilbey T; Daveson K; Reuter SE; Penm J; Alffenaar JW
Int J Antimicrob Agents; 2023 May; 61(5):106783. PubMed ID: 36921808
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.
Pea F; Viale P; Cojutti P; Del Pin B; Zamparini E; Furlanut M
J Antimicrob Chemother; 2012 Aug; 67(8):2034-42. PubMed ID: 22553142
[TBL] [Abstract][Full Text] [Related]
20. Systematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.
Galar A; Valerio M; Muñoz P; Alcalá L; García-González X; Burillo A; Sanjurjo M; Grau S; Bouza E
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
